Ainos, Inc.

Equities

AIMD

US00902F3038

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 17:49:40 27/06/2024 BST			5-day change	1st Jan Change
0.8504 ^USD	+0.63%		-1.89%	-58.52%

06-14	Ainos, Inc. Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA	CI
05-15	Ainos to Start Clinical Trial of Potential Animal Drug for Oral Disease Treatment	MT

Amarillo Biosciences Inc. Announces Resignation of Joseph M Cummins as President and COO

December 05, 2012 at 10:28 pm

Amarillo Biosciences Inc. announced resignation of Dr. Joseph M Cummins as President and COO of the company effective November 30, 2012. As of December 1, 2012 he will begin working for the company as a consultant.

Latest news about Ainos, Inc.

Ainos, Inc. Unveils Critical Progress in Ainos Flora Clinical Trials and Next-Gen Plans Powered by NVIDIA CUDA	06-14	CI
Ainos to Start Clinical Trial of Potential Animal Drug for Oral Disease Treatment	05-15	MT
Ainos, Inc. to Initiate Clinical Study of New Potential VELDONA-Based Animal Drug, Expanding VELDONA's Potential Market	05-15	CI
Earnings Flash (AIMD) AINOS Reports Q1 Revenue $20,729	05-13	MT
Ainos, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
Ainos, Inc. Appoints Christopher Hsin-Liang Lee as Chief Financial Officer	03-19	CI
Ainos, Inc. Announces Resignation of Meng-Lin Sung, the Chief Financial Officer	03-15	CI
Traders Anticipate Inflation Report as US Equities Open Lower on Wall Street	03-11	MT
Top Premarket Decliners	03-11	MT
Ainos, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-08	CI
Top Premarket Gainers	03-08	MT
Ainos Submits Clinical Hold Complete Response to US FDA to Address Issues in Phase 2 Veldona Trial	02-05	MT
Ainos, Inc. Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase Ii Trial of Its Veldona Formulation Against Mild Covid-19 Symptoms	02-05	CI
Ainos, Inc. Enters into Five-Year Product Development Agreement with Taiwan Carbon Nano Technology Corporation	01-12	CI
Wall Street Set to Open Lower as Monthly Jobs Data Much Stronger Than Expected	01-05	MT
Ainos Regains Compliance With Nasdaq Listing Rule	01-02	MT
Ainos, Nisshinbo Micro Devices and Inabata Initiate Phase 2 of VOC Co-Development Powered by Ai Nose, Accelerating the Digitalization of Smell	12-26	CI
Ainos, Inc. Announces Resignation of John Junyong Lee as Chief Legal Counsel and Corporate Secretary	12-22	CI
Ainos Says Three Clinical Studies for Veldona Show 'Positive' Data	11-21	MT
Ainos, Inc. Announces Positive Data Reports from its Clinical Studies for VELDONA as Potential Treatment of Oral Warts in HIV-Seropositive Patients, an Orphan Drug Designated by the FDA	11-21	CI
Earnings Flash (AIMD) AINOS Reports Q3 Revenue $24,489	11-09	MT
Ainos, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-09	CI
Ainos, Inc. Signs MoU for Contract Clinical Trials to Conduct Clinical Study of Potential New Animal Drug Based on Veldona	11-06	CI
Ainos to Issue Preliminary $3 Million Portion of Expected $10 Million Notes Placement	25/09/23	MT
Ainos Says Candidate Treatment for HIV Oral Warts Gets Orphan Drug Designation	18/09/23	MT

Chart Ainos, Inc.

Duration

Period

More charts

Company Profile

Ainos, Inc. is a diversified healthcare company, which is focused on the development of point-of-care testing (POCT), low-dose VELDONA interferon therapeutics and synthetic Ribonucleic Acid (RNA)-driven preventative medicine. The Company's products include VELDONA clinical-stage human therapeutics, VELDONA Pet cytoprotein health supplements, and telehealth-friendly POCTs powered by its AI Nose technology platform. VELDONA Pet is formulated to address a variety of health issues in dogs and cats, including skin, gum, emotion, discomfort caused by allergies, eye, and weight-related issues. Its pipeline of products, which are under development, includes VELDONA human drugs, VOC POCT-Ainos Flora, VOC platform-NISD co-development, VOC POCT-Ainos Pen, VOC POCT-CHS430 and Synthetic RNA. VELDONA human drugs are the high-priority programs include oral warts for human immunodeficiency virus seropositive patients, common cold, influenza, Sjogrens syndrome and treatment for mild COVID-19 symptoms.

Sector

Biotechnology & Medical Research

Calendar

11/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
AINOS, INC.	-58.52%	5.5M
VERTEX PHARMACEUTICALS INCORPORATED	+16.55%	122B
REGENERON PHARMACEUTICALS, INC.	+19.94%	115B
ARGENX SE	+21.22%	26.64B
BIONTECH SE	-23.38%	19.91B
GENMAB A/S	-17.47%	16.32B
WUXI APPTEC CO., LTD.	-45.95%	15.52B
BEIGENE, LTD.	-18.80%	15.49B
SAREPTA THERAPEUTICS, INC.	+61.59%	14.83B
NEUROCRINE BIOSCIENCES, INC.	+3.35%	13.67B

Bio Therapeutic Drugs